000 06351nam a2200709 i 4500
001 on1393438614
003 EBZ
005 20251029164108.0
006 m d
007 cr cnu---unuuu
008 230814s2024 flua o 000 0 eng d
040 _aEBZ
_beng
_cEBZ
020 _a9781003274568
_q(electronic bk.)
020 _a1003274560
_q(electronic bk.)
020 _a9781000957549
_q(electronic bk. : PDF)
020 _a1000957543
_q(electronic bk. : PDF)
020 _a1000957608
_q(electronic bk. : EPUB)
020 _a9781000957600
_q(electronic bk.)
020 _z9781032228662
020 _z1032228660
024 7 _a10.1201/9781003274568
_2doi
037 _a9781003274568
_bTaylor & Francis
050 4 _aRS380
072 7 _aMED
_x009000
_2bisacsh
072 7 _aMED
_x071000
_2bisacsh
072 7 _aTEC
_x009010
_2bisacsh
072 7 _aLNTM2
_2bicssc
049 _aMAIN
245 0 0 _a3D printing and bioprinting for pharmaceutical and medical applications /
_cedited by Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa, Jon Zarate Sesma.
264 1 _aBoca Raton :
_bCRC Press,
_c2024.
300 _a1 online resource :
_billustrations.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
341 0 _atextual
_2sapdv
_3EBSCOhost
490 0 _aEmerging materials and technologies
520 _aThe increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D Printing and Bioprinting for Pharmaceutical and Medical Applications discusses emerging approaches related to these game-changer technologies in such areas as drug development, medical devices, and bioreactors. Key Features: Offers an overview of applications, the market, and regulatory analysis Analyzes market research of 3D printing and bioprinting technologies Reviews 3D printing of novel pharmaceutical dosage forms for personalized therapies and for medical devices, as well as the benefits of 3D printing for training purposes Covers 3D bioprinting technology, including the design of polymers and decellularized matrices for bio-inks development, elaboration of 3D models for drug evaluation, and 3D bioprinting for musculoskeletal, cardiovascular, central nervous system, ocular, and skin applications Provides risk-benefit analysis of each application Highlights bioreactors, regulatory aspects, frontiers, and challenges This book serves as an ideal reference for students, researchers, and professionals in materials science, bioengineering, the medical industry, and healthcare.
532 0 _3EBSCOhost
_a"EBSCO evaluates our products based on the Web Content Accessibility Guidelines (WCAG) and the related Section 508 and EN 301 549 regulations in the US and EU. Most EBSCO products are substantially conformant with WCAG 2.2 level AA." Source: https://connect.ebsco.com/s/article/EBSCO-VPATs?language=en_US. Last accessed April 22, 2025.
545 0 _aJosé Luis Pedraz is Professor and principal researcher in the NanoBioCel group at the University of the Basque Country (UPV/EHU). The research group belongs to the CIBER-BBN of the Carlos III Health Institute, where he serves as the head and director of the medicine formulation laboratory (ICTS) Nanbiosis. Dr. Pedraz is also founder and director of the Pharmaceutical Development Unit of the Basque Country, currently TECNALIA Pharma Labs integrated in the TECNALIA Corporation within a joint project with the UPV/EHU, of which he is scientific director. He had a PhD in Pharmacy from the University of Salamanca. Gustavo Puras is Professor at University of the Basque Country (UPV/EHU), Department of Pharmacy and Food Sciences. He is a member of the NanoBioCel research group at UPV/EHU and the National System of Researchers of Mexico (SNI). He is Professor in the Master's Program of Pharmacology, Development, Evaluation and Rational Use of Medicines at UPV/EHU. He received a PhD in Pharmacy from UPV/EHU. Laura Saenz del Burgo is Professor at the University School of Nursing in Vitoria-Gasteiz and Associate Professor at University of the Basque Country (UPV/EHU) in the Department of Pharmacy and Food Sciences. She is a member of the NanoBioCel research group at UPV/EHU and part of the CIBER-BBN and gives technical assistance to the Nanbiosis platform (Drug Formulation). She received the PhD in Pharmacy from UPV/EHU and has worked as a postdoctoral researcher at the Institute of Molecular, Cell and Systems Biology, University of Glasgow. Jon Zarate is Associate Professor, Department of Pharmacy and Food Sciences, Professor of the Doctoral Program in Drug Research and Evaluation, Application of Pharmaceutical Technology to the Development of Advanced Therapies, and Professor in the Master's Program in Pharmacology, Development, Evaluation and Rational Use of Medicines at University of the Basque Country (UPV/EHU). He is a member of the NanoBioCel research group at the same institution. He received a PhD in Pharmacy from UPV/EHU.
588 0 _aPrint version record.
650 0 _aBiotechnology.
_965162
650 0 _aThree-dimensional printing.
_965163
650 0 _aPharmaceutical biotechnology.
_965164
650 2 _aBiotechnology
_965162
650 2 _aPrinting, Three-Dimensional
_965165
650 7 _abioengineering.
_2aat
_965166
650 7 _a3-D printing.
_2aat
_965167
650 7 _aMEDICAL / Biotechnology
_2bisacsh
_963891
650 7 _aMEDICAL / Pharmacology
_2bisacsh
_964250
650 7 _aTECHNOLOGY / Engineering / Chemical & Biochemical
_2bisacsh
_963924
700 1 _aPedraz Muñoz, Jose Luis,
_eeditor.
_965168
700 1 _aSaenz del Burgo Martínez, Laura,
_eeditor.
_965169
700 1 _aPuras Ochoa, Gustavo,
_eeditor.
_965170
700 1 _aZarate Sesma, Jon,
_eeditor.
_965171
776 0 8 _iPrint version:
_t3D printing and bioprinting for pharmaceutical and medical applications.
_dBoca Raton : CRC Press, 2023
_z9781032228662
856 4 0 _3EBSCOhost
_uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3656808
938 _aYBP Library Services
_bYANK
_n19663546
938 _aEBSCOhost
_bEBSC
_n3656808
994 _a92
_bN$T
999 _c56141
_d56141